BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 27345554)

  • 1. [Metastatic medullary thyroid carcinoma in a child with multiple endocrine neoplasia 2B. Efficiency of medium-term treatment with vandetanib without thyroid surgery].
    Segura D; Dupuis C; Chabre O; Piolat C; Durand C; Plantaz D
    Arch Pediatr; 2016 Aug; 23(8):840-4. PubMed ID: 27345554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma.
    Fox E; Widemann BC; Chuk MK; Marcus L; Aikin A; Whitcomb PO; Merino MJ; Lodish M; Dombi E; Steinberg SM; Wells SA; Balis FM
    Clin Cancer Res; 2013 Aug; 19(15):4239-48. PubMed ID: 23766359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of Vandetanib in Metastatic Medullary Carcinoma of Thyroid in a Pediatric Patient With Multiple Endocrine Neoplasia 2B.
    Narayanan VK; Ronghe M; MacGregor FB; Bradshaw N; Davidson R; Welbury R; Reed N; Shaikh MG
    J Pediatr Hematol Oncol; 2016 Mar; 38(2):155-7. PubMed ID: 26479990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medullary thyroid carcinoma in children.
    Viola D; Romei C; Elisei R
    Endocr Dev; 2014; 26():202-13. PubMed ID: 25231454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Continued Discontinuation of TKI Treatment in Medullary Thyroid Carcinoma - Lessons From Individual Cases With Long-Term Follow-Up.
    Brandenburg T; Tiedje V; Muchalla P; Theurer S; Weber F; Schmid KW; Dralle H; Führer D
    Front Endocrinol (Lausanne); 2021; 12():718418. PubMed ID: 34659114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vandetanib Tumor Shrinkage in Metastatic Medullary Thyroid Cancer Allowing Surgical Resection of the Primary Site: A Case Report.
    Milner TD; Ronghe M; Shaikh MG; MacGregor FB; Reed N
    J Pediatr Hematol Oncol; 2019 Jul; 41(5):e329-e332. PubMed ID: 30334899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vandetanib for the treatment of advanced medullary thyroid cancer outside a clinical trial: results from a French cohort.
    Chougnet CN; Borget I; Leboulleux S; de la Fouchardiere C; Bonichon F; Criniere L; Niccoli P; Bardet S; Schneegans O; Zanetta S; Schvartz C; Drui D; Chauffert B; Rohmer V; Schlumberger M
    Thyroid; 2015 Apr; 25(4):386-91. PubMed ID: 25627619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cabozantinib and vandetanib for unresectable locally advanced or metastatic medullary thyroid cancer: a systematic review and economic model.
    Tappenden P; Carroll C; Hamilton J; Kaltenthaler E; Wong R; Wadsley J; Moss L; Balasubramanian S
    Health Technol Assess; 2019 Feb; 23(8):1-144. PubMed ID: 30821231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes of Children and Adolescents with Advanced Hereditary Medullary Thyroid Carcinoma Treated with Vandetanib.
    Kraft IL; Akshintala S; Zhu Y; Lei H; Derse-Anthony C; Dombi E; Steinberg SM; Lodish M; Waguespack SG; Kapustina O; Fox E; Balis FM; Merino MJ; Meltzer PS; Glod JW; Shern JF; Widemann BC
    Clin Cancer Res; 2018 Feb; 24(4):753-765. PubMed ID: 29187393
    [No Abstract]   [Full Text] [Related]  

  • 10. [Vandetanib, in the management of patients with locally advanced or metastatic medullary thyroid carcinomas].
    Chougnet CN; Schlumberger M; Leboulleux S; Baudin E
    Bull Cancer; 2014 Sep; 101(9):891-5. PubMed ID: 25296193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The safety and efficacy of vandetanib in the treatment of progressive medullary thyroid cancer.
    Fallahi P; Ferrari SM; Baldini E; Biricotti M; Ulisse S; Materazzi G; Miccoli P; Antonelli A
    Expert Rev Anticancer Ther; 2016 Nov; 16(11):1109-1118. PubMed ID: 27650489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-World Efficacy and Safety of Cabozantinib and Vandetanib in Advanced Medullary Thyroid Cancer.
    Koehler VF; Adam P; Frank-Raue K; Raue F; Berg E; Hoster E; Allelein S; Schott M; Kroiss M; Spitzweg C
    Thyroid; 2021 Mar; 31(3):459-469. PubMed ID: 32781914
    [No Abstract]   [Full Text] [Related]  

  • 13. Pregnancy on vandetanib in metastatic medullary thyroid carcinoma associated with multiple endocrine neoplasia type 2B.
    Thomas N; Glod J; Derse-Anthony C; Baple EL; Osborne N; Sturley R; Vaidya B; Newbold K; Brooke A
    Clin Endocrinol (Oxf); 2018 May; 88(5):754-756. PubMed ID: 29457255
    [No Abstract]   [Full Text] [Related]  

  • 14. Vandetanib for the Management of Advanced Medullary Thyroid Cancer: A Real-World Multicenter Experience.
    Kim M; Yoon JH; Ahn J; Jeon MJ; Kim HK; Lim DJ; Kang HC; Kim IJ; Shong YK; Kim TY; Kim BH
    Endocrinol Metab (Seoul); 2020 Sep; 35(3):587-594. PubMed ID: 32981301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vandetanib in a Child Affected by Neurofibromatosis Type 1 and Medullary Thyroid Carcinoma with Both
    Demir Gündoğan B; Sağcan F; Tuğ Bozdoğan S; Balcı Y; Tuncel Daloğlu F; Çağlar Çıtak E
    J Clin Res Pediatr Endocrinol; 2021 Aug; 13(3):342-346. PubMed ID: 32702947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Update on the Treatment of Medullary Thyroid Carcinoma in Patients with Multiple Endocrine Neoplasia Type 2.
    Ilanchezhian M; Khan S; Okafor C; Glod J; Del Rivero J
    Horm Metab Res; 2020 Aug; 52(8):588-597. PubMed ID: 32299110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vandetanib and the management of advanced medullary thyroid cancer.
    Campbell MJ; Seib CD; Gosnell J
    Curr Opin Oncol; 2013 Jan; 25(1):39-43. PubMed ID: 23202050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medullary thyroid carcinoma - Adverse events during systemic treatment: risk-benefit ratio.
    Maciel LMZ; Magalhães PKR
    Arch Endocrinol Metab; 2017; 61(4):398-402. PubMed ID: 28658345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I/II Trial of Vandetanib and Bortezomib in Adults with Locally Advanced or Metastatic Medullary Thyroid Cancer.
    Del Rivero J; Edgerly M; Ward J; Madan RA; Balasubramaniam S; Fojo T; Gramza AW
    Oncologist; 2019 Jan; 24(1):16-e14. PubMed ID: 30297385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-Term Control of Hypercortisolism by Vandetanib in a Case of Medullary Thyroid Carcinoma with a Somatic RET Mutation.
    Paepegaey AC; Cochand-Priollet B; Louiset E; Sarfati PO; Alifano M; Burnichon N; Bienvenu-Perrard M; Lahlou N; Bricaire L; Groussin L
    Thyroid; 2017 Apr; 27(4):587-590. PubMed ID: 28068878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.